IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Meta

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. TTEC
5. DAL
6. AWK
7. SPCX
8. III
9. DFTX
10. BCBP

Go back to IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Meta
(NASDAQ: IDYA) Delayed: 31.23 -0.03 (0.1%)
Previous Close $31.26    52 Week High $ 
Open $31.84    52 Week Low $ 
Day High $32.34    P/E N/A 
Day Low $30.65    EPS $ 
Volume 2,018,518